American Society for Microbiology

Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity

Although the live-attenuated measles virus (MeV) is one of the safest and most efficacious human vaccines, a measles-vectored COVID-19 vaccine candidate expressing the SARS-CoV-2 spike failed to elicit neutralizing antibody (nAb) responses in a phase-1 clinical trial, especially in measles-immune individuals.

Medical Life Sciences

Researchers generate a remodeled live-attenuated measles vaccine capable of driving nAb responses against SARS-CoV-2 spike protein

In a recent study researchers developed a measles virus (MeV)-vectored vaccine capable of inducing high neutralizing antibody (nAb) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Naik et al.

Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer

Mol Cancer Ther. 2018 Jan;17(1):316-326. doi: 10.1158/1535-7163.MCT-17-0432. Epub 2017 Nov 20.

Lauro Velazquez-Salinas et al.

Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV

Hum Gene Ther Clin Dev. 2017 Jun 1; 28(2): 108–115.

Zhang et al.

Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model

Mol Ther. 2016 Dec; 24(12): 2109–2117.

LeBlanc et al.

Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.

Naik et al.

Curative one-shot systemic virotherapy in murine myeloma

Leukemia. 2012 Aug;26(8):1870-8. doi: 10.1038/leu.2012.70. Epub 2012 Mar 19.